Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

May 17, 2026Open Access

Ver artículo completo

Investigations of remibrutinib in models pertinent to multiple sclerosis

Puntos clave

This research aims to evaluate the effects of remibrutinib on inflammatory outcomes in models related to multiple sclerosis.
Utilized models pertinent to multiple sclerosis (MS)
Examined effects on memory B cells in mice
Awaited Phase 3 clinical trial results
Remibrutinib favorably affects inflammatory outcomes in MS models
Specific data on event rates or metrics not reported due to ongoing trials

Resumen

memory B cells in mice. While Phase 3 clinical trial results in MS are awaited, the drug favorably affects inflammatory outcomes in MS models.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Jain et al. (Wed,) studied this question.

synapsesocial.com/papers/6a095a877880e6d24efe07bd https://doi.org/https://doi.org/10.1016/j.neurot.2026.e00923

Investigations of remibrutinib in models pertinent to multiple sclerosis | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Bruton’s Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages2018 · 37 citations
2An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization2005 · 157 citations
3Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis2016 · 1,975 citations
4Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity2017 · 271 citations
5Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis2012 · 268 citations